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Abstract
Background: The CONSORT Statement provides recommendations for reporting randomized controlled
trials. We assessed the extent to which leading medical journals that publish reports of randomized trials
incorporate the CONSORT recommendations into their journal and editorial processes.
Methods: This article reports on two observational studies. Study 1: We examined the online version of
'Instructions to Authors' for 165 high impact factor medical journals and extracted all text mentioning the
CONSORT Statement or CONSORT extension papers. Any mention of the International Committee of Medical
Journal Editors (ICMJE) or clinical trial registration were also sought and extracted. Study 2: We surveyed the
editor-in-chief, or editorial office, for each of the 165 journals about their journal's endorsement of CONSORT
recommendations and its incorporation into their editorial and peer-review processes.
Results: Study 1: Thirty-eight percent (62/165) of journals mentioned the CONSORT Statement in their online
'Instructions to Authors'; of these 37% (23/62) stated this was a requirement, 63% (39/62) were less clear in their
recommendations. Very few journals mentioned the CONSORT extension papers. Journals that referred to
CONSORT were more likely to refer to ICMJE guidelines (RR 2.16; 95% CI 1.51 to 3.08) and clinical trial
registration (RR 3.67; 95% CI 2.36 to 5.71) than those journals which did not.
Study 2: Thirty-nine percent (64/165) of journals responded to the on-line survey, the majority were journal
editors. Eighty-eight percent (50/57) of journals recommended authors comply with the CONSORT Statement;
62% (35/56) said they would require this. Forty-one percent (22/53) reported incorporating CONSORT into
their peer-review process and 47% (25/53) into their editorial process. Eighty-one percent (47/58) reported
including CONSORT in their 'Instructions to Authors' although there was some inconsistency when cross
checking information on the journal's website. Sixty-nine percent (31/45) of journals recommended authors
comply with the CONSORT extension for cluster trials, 60% (27/45) for harms and 42% (19/45) for non-
inferiority and equivalence trials. Few journals mentioned these extensions in their 'Instructions to Authors'.
Conclusion: Journals should be more explicit in their recommendations and expectations of authors regarding
the CONSORT Statement and related CONSORT extensions papers.
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Background
It is over ten years since the CONSORT (Consolidated
Standards of Reporting Trials) Statement was first pub-
lished in 1996 [1] providing recommendations for report-
ing parallel group randomized controlled trials (RCTs).
CONSORT provides recommendations for authors
regarding how to prepare reports of trial findings, facilitat-
ing their complete and transparent reporting, and aiding
their critical appraisal and interpretation. It has been
endorsed by the World Association of Medical Editors
(WAME), the International Committee of Medical Journal
Editors (ICMJE), the Council of Science Editors (CSE),
and well over 200 journals worldwide [2]. The revised
CONSORT Statement of 2001 [3] has been translated into
several languages and cited in journals over 1,300 times.
In addition to the CONSORT Statement, which provides
recommendations for reporting parallel group rand-
omized trials, extensions have been developed to give
additional guidance for randomized trials with specific
designs, data and interventions. These included the CON-
SORT extensions for cluster trials [4], non-inferiority and
equivalence trials [5], herbal interventions [6], non-phar-
macological interventions [7], abstracts [8] and harms [9].
Several studies have assessed the impact of using the
CONSORT Statement to improve the reporting of RCTs in
journal articles. Eight studies were summarized in a sys-
tematic review by Plint and colleagues [10], who con-
cluded that journal adoption of the CONSORT Statement
is associated with improved reporting of randomized tri-
als although poor reporting remains common.
In 2003, Altman conducted a study of journal endorse-
ment of the CONSORT Statement and found that seven
years following its initial publication, and two years after
its update, only 22% of 166 high impact factor journals
provided any mention of CONSORT in their published
'Instructions to Authors' [2]. Four years have elapsed since
this journal endorsement survey and we believe it is again
timely to assess the impact of the CONSORT Statement
and determine the extent to which journals that publish
reports of randomized trials incorporate the CONSORT
recommendations into their journal and editorial proc-
esses.
Objectives
We set out to determine the extent to which leading med-
ical journals incorporate the CONSORT Statement and
related extension papers in their published 'Instructions
to Authors'. We also sought to survey journal editors'
opinions about endorsement of the CONSORT Statement
and related CONSORT extension papers and their incor-
poration into the editorial and peer-review process.
Methods
Sample
Journals were selected using the strategy adopted by Alt-
man [2]. Using citation impact factors (via ISI Web of
Knowledge) for 2006, we identified the top five journals
from each of the 33 medical specialties and the top 15
journals for general and internal medicine. Journals that
did not publish clinical research (based on explicit state-
ment or inspection of journal contents) were excluded
and replaced by the next one on the list.
Survey of journals' published 'Instructions to Authors'
For each of the journals in the sample, we examined the
'Instructions to Authors' published on the journal's web-
site (searched between July and October 2007) and
extracted all text mentioning CONSORT or CONSORT
extension papers (cluster, non-inferiority and equiva-
lence, herbal and harms). Any mention of the ICMJE's
'Uniform Requirements for Manuscripts Submitted to
Biomedical Journals' or reference to clinical trial registra-
tion were also sought and extracted.
Survey of journal editors
For each of the journals in the sample, we contacted via
email the editor-in-chief, or editorial office if contact
details for this person were not available (depending on
the contact information included on the journal website),
asking them to complete a short on-line survey (con-
ducted between 6 August and 8 October 2007 using Sur-
vey Monkey). Two email reminders were sent to
encourage editors to complete the on-line survey. The sur-
vey asked about their journal's endorsement of the CON-
SORT Statement, whether CONSORT is included in their
'Instructions to Authors', and if it is incorporated into
their editorial and peer-review processes and, if so, how.
Journal editors were also asked whether they recom-
mended or required authors to comply with any of the
CONSORT extension papers (cluster, non-inferiority and
equivalence, herbal and harms). The on-line survey of
journal editors' endorsement of CONSORT allows a direct
comparison with what is reported in their journal's pub-
lished 'Instructions to Authors' on their journal's website.
Results
One hundred and eighty journals were identified, of
which 15 were duplicates (i.e. listed in another medical
speciality) and excluded; 165 journals were included in
our sample.
Survey of journals' published 'Instructions to Authors'
Of the 165 journals, 62 (38%) mentioned the CONSORT
Statement in their 'Instructions to Authors' published on
their journal's website. This is a relative increase of 73%
from the survey in 2003 [2], when 36 (22%) of the 166
journals provided any mention of CONSORT. One-hun-Trials 2008, 9:20 http://www.trialsjournal.com/content/9/1/20
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dred and twenty-one journals were included in both the
2003 and 2007 samples; of these, 32 (26%) of 121 jour-
nals in 2003 provided any mention of CONSORT com-
pared to 47 (39%) in 2007, a relative increase of 50%.
Twenty-three of the 62 journals that mentioned the CON-
SORT Statement in their 'Instructions to Authors' stated
that this was a requirement of their journal (i.e. authors
must conform to the CONSORT Statement) (Table 1). Of
Table 1: Mentioned in journals published 'Instructions to Authors'
N = 165 (%)
CONSORT Statement 62 (38%)
Require 23
Recommend 39
Submit with checklist 17
Web address 46 *
2001 journal article 18
2001 exploratory article 1
Article citing 2001 article 2
1996 journal article (out-of-date) 6 **
Cluster extension 5 (3%)
Require 3
Recommend 2
Suitable reference 2
Harms extension 3 (2%)
Require 2
Recommend 1
Suitable reference 1
Herbal extension 2 (1%)
Recommend 2
Suitable reference 2
Non-inferiority and equivalence extension 1 (1%)
Recommend 1
Suitable reference 1
ICMJE 69 (42%)
Web address 48
Suitable reference (article > 2000) 3
Obsolete reference (article < 2000) 15
No reference 6
Trial registration 61 (37%)
Require 44
Recommend 17
Cites http://www.icmje.org 23
Cites http://www.clinicaltrials.gov 9
Cites WHO International Clinical Trial Registry Platform 4
Cites a combination of the above 10
* Web address was misspelt (n = 2)
** Article citing the 1996 article (n = 1)Trials 2008, 9:20 http://www.trialsjournal.com/content/9/1/20
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these, 17 stated that they required a completed CONSORT
checklist to be submitted with the manuscript as a condi-
tion of the submission. The remaining 39 journals were
less clear in their recommendations and included phrases
such as authors "should consult the CONSORT guide-
lines" or "we encourage authors to follow the CONSORT
Statement". Very few journals provided any mention of
the CONSORT extension papers (cluster (n = 5), non-infe-
riority and equivalence (n = 1), herbal (n = 2) and harms
(n = 3)).
The majority of journals (n = 46) mentioning the CON-
SORT Statement gave the web address [11], while 18
referred to the latest version of the publication. Only one
journal referred to the full explanatory publication [12],
however, and six journals still referred to the out-of-date
1996 Statement [1].
Of the 165 journals, 69 (42%) referred to the ICMJE
guidelines in their published 'Instructions to Authors'.
This is a slight decrease from when this survey was last car-
ried out in 2003, when 72 of the 166 (43%) journals
referred to the ICMJE guidelines. The majority of journals
(n = 48) referred to ICMJE the web address, including
three which also referred to a recent publication. The
remaining 15 journals cited an obsolete journal publica-
tion (i.e. published before 2000), while six included no
reference. Journals that referred to CONSORT were much
more likely to refer to the ICMJE guidelines (39/62; 63%)
than those journals that did not refer to CONSORT (30/
103; 29%) (relative risk 2.16; 95% confidence interval
(CI) 1.51 to 3.08).
Sixty-one (37%) of the 165 journals mentioned clinical
trial registration in their 'Instruction to Authors', of which
44 specifically stated that all recent clinical trials must be
registered as a requirement of submission to that journal.
A further 17 journals were less clear in their recommenda-
tions and, while they encouraged clinical trial registration,
this was not a specific requirement. Cited sources of infor-
mation about trial registration included the ICMJE web
address (n = 23), ClinicalTrials.gov (n = 9) and the WHO
International Clinical Trials Registry Platform (n = 4); the
other 10 journals cited a combination of these sources.
Again, journals that referred to CONSORT were much
more likely to mention clinical trial registration (42/62;
68%) than those journals that did not refer to CONSORT
(19/103; 18%) (relative risk 3.67; 95% CI 2.36 to 5.71).
Those journals which provided some mention of the
CONSORT Statement in their 'Instructions to Authors'
were also much more likely to include information about
other reporting guidelines. These included QUOROM
(13/165; 8%), MOOSE (7/165; 4%), REMARK (1/165;
1%), STROBE 4/165; 2%) and TREND (1/165; 1%); all
mentioned CONSORT in their 'Instructions to Authors'.
Survey of journal editors
Responses were received from 64 (39%) of the 165 jour-
nals to the on-line survey of journal editors about
endorsement of the CONSORT Statement and related
CONSORT extension papers (not all journals responded
to each section of the survey). The majority of responders
were journal editors (Table 2). Thirty-nine (61%) of the
64 responders reported that the CONSORT Statement was
mentioned in the 'Instructions to Authors' on their jour-
nal's website.
For 50 (50/57; 88%) journals, responders said that their
journal recommended that authors comply with the
Table 2: Survey of journals editors' endorsement of the CONSORT Statement
N = 64* (%)
Person completing survey
Editor in chief 18 (28%)
Managing editor 17 (27%)
Associate editor 7 (11%)
Editor 4 (6%)
Administrator 16 (25%)
Other (director) 2 (3%)
Journal recommends authors comply with the CONSORT Statement 50/57 (88%)
Not applicable 2/57 (3%)
Journal requires authors comply with the CONSORT Statement 35/56 (62%)
Not applicable 2/56 (4%)
Journal mentions the CONSORT Statement in its 'Instructions to Authors' 47/58 (81%)
Not applicable 2/58 (3%)
Journal incorporates the CONSORT Statement in its peer review process 22/53 (41%)
Journal incorporates the CONSORT Statement in its editorial process 25/53 (47%)
* Some responders did not complete all sections of the survey.Trials 2008, 9:20 http://www.trialsjournal.com/content/9/1/20
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CONSORT Statement; for 35 (35/56; 62%) journals this
was a requirement (Table 2). Most respondents (47/58;
81%) also said that their journal mentioned the CON-
SORT Statement in its 'Instructions to Authors'. However,
there is some inconsistency, as when subsequently cross
checking the information provided on the journal's web-
site under 'Instructions to Authors', 11 of the 47 journals
provided no mention of the CONSORT Statement despite
indicating in the on-line survey that they did.
Just under half of journals (22/53; 41%) said that they
incorporated the CONSORT Statement into their peer-
review process. A similar proportion of journals (25/53;
47%) said that they incorporated the CONSORT State-
ment into their editorial process. Examples of how this
was achieved include "requiring authors to include a
CONSORT flow diagram and completed checklist with
their manuscript submission", "editors pre-screening and
returning non compliant manuscripts directly to the
authors", "including the CONSORT checklist for down-
load on the peer review website alongside the submitted
manuscript", "including information about the CON-
SORT Statement in the instructions for peer review", and
"including the CONSORT Statement as part of the edito-
rial checklist".
Journal editors were also asked about their journal's
endorsement of extensions to the CONSORT Statement.
Thirty-one (69%) journals said that their journal recom-
mended authors comply with the CONSORT extension
for cluster trials; 22 (49%) journals said that they would
require this (Table 3). Twenty-seven (60%) said that their
journal recommended authors comply with the CON-
SORT extension for harms and 18 (40%) said that they
would require this. Nineteen (42%) journals said that
their journal recommended authors comply with the
CONSORT extension for non-inferiority and equivalence
trials whereas 13 (29%) journals said that they would
require this. The CONSORT extension for herbal interven-
tions was not as widely endorsed as it was not applicable
for some journals.
Despite journal editors' responses about extensions to the
CONSORT Statement, few actually mentioned these
extensions in their 'Instructions to Authors' (Table 3).
Discussion
The CONSORT Statement aims to improve the quality of
reports of randomized trials. It is encouraging that over a
third (38%) of high impact factor journals, assessed in our
study, refer to the CONSORT Statement in their published
'Instruction to Authors'. This represents a relative increase
of 73% since this study was last conducted in 2003 when
only 22% of journals mentioned CONSORT in their
'Instruction to Authors' [2]. Some journals, however, still
refer to the superseded 1996 version of the CONSORT
Statement and we would encourage journals to keep their
'Instructions to Authors' up-to-date.
There is, however, still ambiguity in the wording of some
journals' published 'Instructions to Authors' as to whether
they require, or recommend, that authors comply with the
CONSORT Statement [2]. We believe that journals should
provide a clear message to their authors and recommend
authors submit a completed CONSORT flow diagram and
checklist as a requirement to submission in an endorsing
journal. Only by endorsement of the CONSORT State-
ment by more journals, and greater editorials efforts to
Table 3: Survey of journals editors' endorsement of extensions to the CONSORT Statement *
Yes No Not applicable
Journal recommends authors comply with the CONSORT
Cluster extension 31 (69%) 10 (22%) 4 (9%)
Harms extension 27 (60%) 11 (24%) 7 (16%)
Herbal extension 13 (29%) 10 (22%) 22 (49%)
Non-inferiority and equivalence extension 19 (42%) 12 (27%) 14 (31%)
Journal requires authors comply with the CONSORT
Cluster extension 22 (49%) 16 (36%) 7 (15%)
Harms extension 18 (40%) 18 (40%) 9 (20%)
Herbal extension 12 (26%) 14 (30%) 20 (44%)
Non-inferiority and equivalence extension 13 (29%) 17 (39%) 14 (32%)
Journal mentions CONSORT extension in its 'Instructions to Authors'
Cluster extension 12 (27%) 28 (62%) 5 (11%)
Harms extension 10 (22%) 29 (65%) 6 (13%)
Herbal extension 5 (12%) 24 (56%) 14 (32%)
Non-inferiority and equivalence extension 5 (12%) 28 (65%) 10 (23%)
* Some responders did not complete all sections of the survey.Trials 2008, 9:20 http://www.trialsjournal.com/content/9/1/20
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ensure that authors comply, can the quality of reporting of
randomized trials published in leading journals be
improved [10].
In September 2004, the members of the ICMJE published
a joint editorial stating that they would only consider a
trial for publication if it has been registered before the
enrolment of the first patient [13]. In our study, over a
third (37%) of journals required recent clinical trials to be
registered as a requirement of submission to that journal.
Disappointingly, a number of these journals did not pro-
vide the same endorsement of the CONSORT Statement
despite recognising the importance of trial registration
which, by itself, is not the best marker of trial quality.
It is also disappointing that so few journals endorse the
recent extensions to the CONSORT Statement [4-6,9].
These extensions reflect a considerable amount of work
and were developed to improve the reporting and trans-
parency of trials using specific designs and types of data.
Other CONSORT extensions have very recently been pub-
lished [7,8] and others are being developed. We would
recommend that journals reference these extensions in
their 'Instructions to Authors' thereby helping authors
wanting to improve the reporting of their randomized tri-
als.
One obvious limitation of our study is that, despite sev-
eral electronic reminders, there was a poor response rate
(39%) to the on-line survey of journal editors' endorse-
ment of CONSORT. As might be expected journals which
endorsed CONSORT were more likely to respond (61%)
to the survey than those journals which did not (39%).
However, despite this limitation the results of this survey
are still of interest, in particular, to those journals who
said they would require, or recommend, authors comply
with the CONSORT Statement but do not mention this in
their 'Instructions to Authors'. This is particularly appar-
ent for CONSORT extensions. In response to the survey
two journal editors said that they were in the process of
updating their journals' 'Instructions to Authors'. It is pos-
sible that these instructions were updated during the
study period; however, the numbers are very small and
would not affect our results. We note however, that there
was inconsistency between editors' responses and the
information on the journal's website under 'Instructions
to Authors', especially in relation to the support of exten-
sions to CONSORT.
Similar to the CONSORT Statement for reporting the
results of randomized trials, other reporting guidelines
exist which provide advice on how to report research
methods and findings for other types of study designs. In
our study journals which endorsed the CONSORT State-
ment were more likely to endorse other reporting guide-
lines, although the numbers were very low. The
EQUATOR Network [14] is a new initiative which aims to
increase awareness of good reporting guidelines in health
research and thus improve the quality of scientific publi-
cations. We hope the work of this initiative will lead to
better endorsement by journals of these important report-
ing guidelines.
Conclusion
In summary, we believe that the CONSORT Statement,
and its related extensions papers, will only continue to
improve the quality of reports of randomized trials, if
more journals endorse this initiative and, most impor-
tantly, require authors to comply as a condition of publi-
cation. The most obvious route through which this could
be achieved is for journals to incorporate the CONSORT
checklist and flow diagram into their editorial and peer-
review processes and reflect this requirement in their pub-
lished 'Instructions to Authors'. Without wide endorse-
ment of the CONSORT Statement it cannot fully yield the
benefits for which it was intended.
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